Insulet Corporation Common Stock (PODD)
Stock · NASDAQ · Health Care
$141.09as of 10/16/2026
Price chart
Active signals
PODD Signal Track Record
How signals performed across all stocks →What PODD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 28 | +0.5% | 54% | October 1, 2026 |
| Bollinger Band Breakdown | 25 | -2.6% | 48% | September 9, 2026 |
| Bollinger Band Breakout | 25 | -1.1% | 44% | July 29, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +10.8% | 70% | August 6, 2025 |
| Any 20-session window (baseline) | -1.1% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values throu…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 5,400
- Website
- www.omnipod.com
Fundamentals
- 1-day range
- $140.23$143.3
- Market cap
- $9.65B
- P/E (trailing)
- 25.40
- P/E (forward)
- 18.29
- EPS (trailing)
- $5.35
- Dividend yield
- —
- Beta
- 1.08
- Avg. volume
- 1.69M
How Insulet Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 18, 2026 · via SEC EDGAR / Finnhub
Forecasts
23 analyst ratings
Insulet Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- PODDInsulet Corporation Common Stock$141.1▲ 1.68%Market cap $9.65BP/E 25.40$126.4$354.88
- GKOSGlaukos Corporation Common Stock$164.84▼ 0.46%Market cap $10.09BP/E —$73.16$191.62
- GMEDGlobus Medical Inc. Class A Common Stock$76.71▼ 2.70%Market cap $11.01BP/E 19.14$56.96$101.4
- TFXTeleflex Incorporated Common Stock$130.43▲ 1.72%Market cap $6.15BP/E —$100.18$145
- STVNStevanato Group S.p.A. Ordinary Shares$18.9▼ 1.82%Market cap $6.14BP/E 34.82$12.89$27.99
- BAXBaxter International Inc. Common Stock$25.28▼ 1.86%Market cap $13.96BP/E —$15.73$30
- MMSIMerit Medical Systems Inc. Common Stock$89.2▼ 0.41%Market cap $5.24BP/E 36.33$59.74$94.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PODD Insulet Corporation Common Stock | $9.65B | 25.40 | $141.1 | ▲ 1.68% | $126.4$354.88 |
| GKOS Glaukos Corporation Common Stock | $10.09B | — | $164.84 | ▼ 0.46% | $73.16$191.62 |
| GMED Globus Medical Inc. Class A Common Stock | $11.01B | 19.14 | $76.71 | ▼ 2.70% | $56.96$101.4 |
| TFX Teleflex Incorporated Common Stock | $6.15B | — | $130.43 | ▲ 1.72% | $100.18$145 |
| STVN Stevanato Group S.p.A. Ordinary Shares | $6.14B | 34.82 | $18.9 | ▼ 1.82% | $12.89$27.99 |
| BAX Baxter International Inc. Common Stock | $13.96B | — | $25.28 | ▼ 1.86% | $15.73$30 |
| MMSI Merit Medical Systems Inc. Common Stock | $5.24B | 36.33 | $89.2 | ▼ 0.41% | $59.74$94.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Jefferies Maintains Buy on Insulet, Lowers Price Target to $190benzinga · 10/12/2026
- Insulet Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · 10/8/2026
- Intel downgraded, Marvell upgraded: Wall Street's top analyst callsYahoo · 10/7/2026
- Barclays Initiates Coverage On Insulet with Equal-Weight Rating, Announces Price Target of $150Benzinga · 10/7/2026
- 2 Safe-and-Steady Stocks to Consider Right Now and 1 Facing ChallengesYahoo · 10/1/2026
- Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026Yahoo · 10/1/2026
- Insulet (NASDAQ:PODD) Offers Affordable Growth With Strong FundamentalsChartMill · 9/30/2026
- Insulet (PODD) Stock May Trade At A Discount To Fair ValueYahoo · 9/26/2026
- 2 Healthcare Stocks with Impressive Fundamentals and 1 Facing ChallengesYahoo · 9/25/2026
Insider Activity
Insider Actions →- Flavia Pease · October 1, 2026 · Tax Withholding1.9K @ $130.79
- Jonathan Jay Mazelsky · September 30, 2026 · Grant141 @ $130.47
- Robert Luther Huffines · September 30, 2026 · Grant178 @ $130.47
- Ashley McEvoy · August 21, 2026 · Buy1.1K @ $147.47
- Lisa Blair Davis · August 1, 2026 · Tax Withholding244 @ $165.35
- Jonathan Jay Mazelsky · July 1, 2026 · Grant1.4K
- Robert Luther Huffines · June 30, 2026 · Grant144 @ $159.79
- Robert Luther Huffines · June 30, 2026 · Grant151 @ $152.25
- Timothy C. Stonesifer · June 3, 2026 · Buy2.8K @ $143.51
- Luciana Borio · June 3, 2026 · Sale418 @ $143.27
- Elizabeth H. Weatherman · June 3, 2026 · Buy3.5K @ $144.2
- Elizabeth H. Weatherman · May 20, 2026 · Grant1.7K
- Timothy C. Stonesifer · May 20, 2026 · Grant1.7K
- Timothy J. Scannell · May 20, 2026 · Grant1.7K
- Michael R. Minogue · May 20, 2026 · Grant1.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 64.99M
- Total value held
- $12.92B
- Institutional holders
- 771
- Unknown6.38M
- Unknown4.58M
- Unknown3.97M
- Unknown3.04M
- Unknown2.03M
- Unknown2.03M
- Unknown1.82M
- Unknown1.67M
- Unknown1.60M
- Unknown1.59M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Insulet Sets Q3 2026 Earnings Date for Nov 4
Insulet has scheduled its third-quarter 2026 financial results for release on November 4, 2026. Recent commentary suggests the company offers affordable growth supported by strong fundamentals. The stock is currently trading near its 52-week low, with technical indicators showing a support rejection and volume spike.
Insulet Sets Q3 2026 Earnings Date for Nov 4. Insulet has scheduled its third-quarter 2026 financial results for release on November 4, 2026. Recent commentary suggests the company offers affordable growth supported by strong fundamentals. The stock is currently trading near its 52-week low, with technical indicators showing a support rejection and volume spike.